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ABSTRACT
To evaluate high-dose therapy and autologous or allogeneic blood or marrow transplantation (BMT) for
mantle cell lymphoma, patients receiving BMT for newly diagnosed or relapsed mantle cell lymphoma were
identified through the registry at Johns Hopkins. The pathologic diagnostic criteria were reviewed, and details
of the presentation, transplant procedure, and survival outcomes were determined. Fifty-eight patients were
identified, of whom 64% underwent transplantation in first remission and 12% had primary induction failure.
Nineteen patients (one third) received an allograft. Preparative regimens consisted of cyclophosphamide in
combination with either busulfan or total body irradiation. On multiple regression analysis, transplantation
after 1 or more relapses (hazard ratio, 2.98; P  .02), primary induction failure (hazard ratio, 5.39; P  .002),
and allogeneic transplantation (hazard ratio, 3.03; P .007) were associated with an inferior event-free survival
(EFS). However, EFS curves were not statistically different for autologous and allogeneic BMT performed in
first remission , with an estimated 3-year EFS approaching or equaling 70%. Primary induction failure and
residual bone marrow involvement were the only statistically significant predictors of relapse on multiple
regression analysis. At 3 years, the estimated EFS for the entire cohort after BMT was 51%, the probability of
relapse was 31%, and the overall survival was 59%. The benefit of autologous or allogeneic BMT for mantle
cell lymphoma is thus most apparent when transplantation is performed in first remission. Whether allogeneic
BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Although at one time regarded as a low-grade
on-Hodgkin lymphoma [1], mantle cell lymphoma is
n aggressive disease that is generally considered in-
urable with conventional chemotherapy. The distinct
atural history mandates that mantle cell lymphoma
utcomes be studied separately from those of other
ymphomas and that the diagnostic criteria be well
eﬁned in analyses of treatment outcomes. Relapse
ften occurs within 12 to 18 months of ﬁrst-line ther-
py, with a typical median survival of 3 to 4 years [2,3].
ccordingly, there has been recent interest in high-
ose systemic therapy with blood or marrow trans-
lantation (BMT) for this disease. The ability of au-
ologous BMT to prolong event-free (EFS) and
verall (OS) survival in mantle cell lymphoma has C
B&MTeen a matter of debate [4-7], and there are relatively
ew data on the role of fully ablative or reduced-
ntensity allogeneic BMT for this disease [8-12]. To
urther investigate the role of autologous and alloge-
eic BMT for mantle cell lymphoma, we report our
nstitutional experience with these high-dose thera-
eutic approaches.
ATERIALS AND METHODS
atient Selection
Through the BMT Registry at Johns Hopkins, the
ecords of patients who received an autologous or
llogeneic BMT for newly diagnosed or relapsed man-
le cell lymphoma at the Johns Hopkins Oncology
enter from 1980 through 2003 were screened. In
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4ddition to the category of mantle cell lymphoma, the
atabase was searched for potential synonyms such as
entrocytic, diffuse intermediately differentiated, or
iffuse poorly differentiated lymphoma [13]. The di-
gnosis of mantle cell lymphoma was based on a com-
ination of morphologic and immunophenotypic
ﬂow cytometry, tissue immunohistochemistry, or
oth) criteria, with or without cytogenetics [13]. In
ddition to basic demographic data, disease status, and
ital status, study variables included presenting clinical
eatures, type of conventional chemotherapy received,
emission status before BMT, morphologic and ﬂow
ytometric bone marrow involvement before BMT,
reparative regimen, stem cell source, graft manipu-
ation, and development of graft-versus-host disease
GVHD).
The achievement of a complete or partial response
o any given therapy was based on determinations of
he treating physicians. Sensitive relapse was deﬁned
s a decrease in tumor size in response to the last
hemotherapeutic regimen given before high-dose
herapy and BMT. Rare cases of untested relapse were
onsidered to be sensitive for the purposes of statisti-
al analysis. Primary induction failure was deﬁned as a
ack of response to ﬁrst-line treatment or disease pro-
ression within 2 months of its completion.
Permission to perform this retrospective case re-
iew was granted by the institutional review board.
his analysis represents events reported through June
4, 2004.
ransplantation
Eligibility guidelines for BMT included adequate
erformance status (Eastern Cooperative Oncology
roup performance status 2 or Karnofsky status
70%); ejection fraction 45%; forced expiratory
olume in 1 second and forced vital capacity 50%;
ilirubin 2.0 mg/dL; creatinine 2.0 mg/dL; and
bsence of human immunodeﬁciency virus infection.
utologous BMT recipients additionally required ad-
quate bone marrow function for harvesting or pe-
ipheral blood mobilization, with 10% residual in-
olvement by lymphoma. Allogeneic transplantation
as generally prioritized in patients 55 years of age
ho had an HLA-identical sibling.
Autografts were derived from bone marrow har-
esting or from peripherally mobilized stem cells. The
tandard mobilization regimen consisted of cyclo-
hosphamide (Cy) followed by granulocyte colony-
timulating factor, with a required yield of at least 2 
06 CD34 cells per kilogram. Allografts in this series
ere derived from related donors through bone mar-
ow harvesting and were T-cell depleted by counter-
ow centrifugal elutriation [14]. All but 1 transplan-
ation used preparative regimens consisting of either
y with total body irradiation (TBI) or busulfan (Bu) w
0ith Cy. Cy/TBI consisted of Cy (50 mg/kg/d for 4
ays) followed by TBI (300 cGy/d for 4 days, with
hielding of the lungs on day 3 and shielding of the
iver in cases of increased transaminases). Bu/Cy con-
isted of Bu (1 mg/kg every 6 hours for 4 days, with
ose adjustments based on pharmacokinetic calcula-
ions) followed by Cy (50 mg/kg/d for 4 days).
Cyclosporine was the ﬁrst-line agent for GVHD
rophylaxis after fully myeloablative allogeneic trans-
lantation. Supportive care—including antibiotic pro-
hylaxis, transfusions, and GVHD prophylaxis and
reatment—was delivered according to standard insti-
utional guidelines or approved clinical protocols in
ffect at that time.
tatistical Methods
The primary statistical end points were EFS and
elapse. EFS was deﬁned as the interval between BMT
nd relapse, diagnosis of myelodysplastic syndrome or
cute leukemia, or death from any cause; patients
ithout such an occurrence were censored at the date
hey were last known to be alive and disease free. OS
as deﬁned as the interval between BMT and the date
f death or the date last known to be alive. To esti-
ate actuarial relapse rates, patients without evidence
f relapse were censored at the date of last assessment
r at the date of death. Survival rates with 95% con-
dence intervals (CI) were estimated with the Kaplan-
eier method [15]. Nonoverlapping survival distribu-
ions were compared between groups with the
og-rank statistic [16], and overlapping survival distri-
utions were compared by using the Tarone test [17].
Analyses of prognostic factors were performed
ith the Cox proportional hazards model [18]. A haz-
rd ratio (HR) 1 indicates the increase in risk of
aving the event relative to the reference category.
he 1 recipient of a syngeneic graft was excluded from
he comparison of autologous and allogeneic trans-
lantation, and the 1 recipient of a nonmyeloablative
ransplant was excluded from the comparison of fully
blative preparative regimens. All P values are 2 sided.
tatistical analysis was performed with Stata version
.0 (Stata Corp., College Station, TX), with the ex-
eption of the Tarone test (SAS version 8.0; SAS
nstitute, Cary, NC).
ESULTS
atient Characteristics
Fifty-eight consecutive patients who received
MT for mantle cell lymphoma were identiﬁed. Their
haracteristics are described in Table 1. The trans-
lants occurred between 1993 and 2003. Other (gen-
rally earlier) cases of suspected mantle cell lymphoma
ere identiﬁed, but insufﬁcient histopathologic and
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BMT for Mantle Cell Lymphoma
Bonﬁrmatory data were available on re-review to per-
it inclusion in this analysis.
The median age at BMT was 55 years, and most
atients (88%) had at least Ann Arbor stage III dis-
able 1. Patient Characteristics (n  58)
Variable Value
ge at BMT, y, median (range) 55 (31-72)
onths from diagnosis to BMT, median (range) 8.6 (3-62)
ale sex 48 (83%)
nitial stage, n (%)
I 4
II 3
III* 11 (19%)
IV 40 (69%)
B” symptoms at diagnosis (n) 6
one marrow involvement at diagnosis (n)
Yes† 39
No 14
Not assessed or indeterminate 5
resentations at diagnosis or relapse, n (%)
Splenomegaly or splenic lesion 20 (34%)
Biopsy-proven lymphomatous polyposis 9 (16%)
Lymphocytosis 12 (21%)
irst-line chemotherapy, n (%)
CHOP  rituximab 41 (71%)
Fludarabine, alone or in combination 10
Hyper-CVAD 2
EPOCH  rituximab 2
Other 3
isease status at BMT, n (%)
First remission 37 (64%)
Complete 16
Partial 21
One or more relapses 14 (24%)
Sensitive 13
Resistant 0
Untested 1
Primary induction failure 7 (12%)
Sensitive 4
Resistant 2
Untested 1
one marrow involvement at BMT (n)
Yes (morphologic) 11
No 44
Flow normal 32
Flow abnormal 7
Flow not done 5
Unknown or indeterminate 3
ype of BMT, n (%)
Autologous 38 (66%)
Allogeneic 19 (33%)
Syngeneic 1
reparative regimen, n (%)
Busulfan, cyclophosphamide 20 (34%)
Cyclophosphamide, TBI 37 (64%)
Fludarabine, TBI (nonmyeloablative) 1
yper-CVAD indicates hyperfractionated cyclophosphamide, vin-
cristine, doxorubicin, and dexamethasone; EPOCH, etoposide,
prednisone, vincristine, cyclophosphamide, and doxorubicin.
Initial bone marrow biopsy was not performed in 3 patients be-
lieved to have stage III disease and 2 patients with stage IV
disease.
Includes 4 cases in which bone marrow biopsy was suggestive of
but not deﬁnitive for lymphomatous involvement.ase. The incidence of bone marrow involvement, *
B&MTplenic involvement, gastrointestinal involvement, and
ymphocytosis is described in Table 1. Most received
HOP (cyclophosphamide, hydroxydaunomycin,
ncovin [vincristine], and prednisone), with or with-
ut rituximab, as ﬁrst-line therapy; ﬂudarabine-based
herapy was the next most common. Most (64%) un-
erwent transplantation in ﬁrst remission, and similar
roportions of patients were in complete and partial
emission before high-dose therapy (Table 1). Of the
4 patients (24%) who underwent transplantation af-
er relapse, only 2 had more than 1 relapse. Seven
atients (12%) had primary induction failure. Of all
he patients in this study, only 2 had resistant relapse
efore high-dose therapy and BMT.
Details of the transplantation are described in Ta-
le 1. Approximately two thirds of patients received
y/TBI, and one third received Bu/Cy. Nineteen pa-
ients (one third) received allogeneic transplants, all
ut 1 of which was fully myeloablative. A subset of
hese allogeneic transplant recipients was included in
n earlier report [8]. Thirty-eight patients (two thirds)
eceived autologous transplants, most commonly
over 80%) with peripherally mobilized, leukapher-
sed, cryopreserved stem cells. One patient received a
yngeneic graft. Twenty-nine (76%) received peri-
ransplantation rituximab according to protocols ap-
roved by the institutional review board. Twenty-six
utografts (68%) were CD34 enriched, and a minority
f autografts were purged with 4-hydroperoxycyclo-
hosphamide [19] (n  5) or were unmanipulated in
itro (n  7).
able 2. Mortality According to Type of BMT
Cause of Death No. Dead
utologous BMT 10
Early transplant related 2
Multiorgan failure 1
Multiorgan failure with VOD 1
Late transplant related 2
Acute leukemia 2
Disease progression 4
Non–cancer related 1
Unknown* 1
llogeneic BMT 11
Early transplant related 6
Multiorgan failure 2
Diffuse alveolar damage 1
CMV pneumonitis 1
Respiratory failure and resistant disease 1
Intracranial hemorrhage 1
Late transplant related 4
Interstitial pneumonitis 1
Bronchopneumonia 1
Disseminated toxoplasmosis 1
GVHD 1
Disease progression 1
OD indicates veno-occlusive disease; GVHD, graft-versus-host
disease; CMV, cytomegalovirus.
he “early transplant” period refers to the ﬁrst 100 days after BMT.
Death occurred more than 8 years after BMT.
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4iagnostic Criteria
In 46 of the 58 cases, the presence of an 11;14
ranslocation was demonstrated by cyclin D1 staining
n  43), cytogenetics, or ﬂuorescence in situ hybrid-
zation. In 6 cases, the diagnosis was based on charac-
eristic morphologic features and the following phe-
otype: CD5, CD23, CD20, and FMC-7. In the
emaining 6 cases, the diagnosis was based on charac-
eristic morphologic features and a partial immuno-
henotype. These 6 patients were diagnosed between
993 and 1997; received either CHOP or ﬂudarabine-
ased regimens as ﬁrst-line therapy; and received
MT (3 autologous and 3 allogeneic) between 1997
nd 2000. The EFS curves are similar with and with-
ut the latter cases (data not shown).
urvival Outcomes
By the last follow-up date, 12 relapses were doc-
mented, 8 of which occurred after autologous BMT.
our patients who received an autologous BMT were
live with relapsed disease. An additional 3 patients in
he autologous group developed myelodysplastic syn-
rome, acute myeloid leukemia, or both; 2 have died
s a result. Eight of the allogeneic transplant recipi-
nts (42%) developed GVHD. One patient in the
llogeneic group was alive with relapse, which oc-
urred more than 4 years after BMT in ﬁrst partial
emission. Causes of death according to the type of
ransplantation are listed in Table 2.
The estimated median EFS and OS of the entire
ohort after BMT were 43 and 52 months, respec-
ively (Figure 1A). The median follow-up time was 16
onths for the entire cohort (range, 1 month to 79
onths) and 23 months for the surviving patients.
he actuarial 3-year EFS was 51% (95% CI, 35%-
5%), and OS was 59% (CI, 42%-73%). The proba-
ility of relapse at 3 years was 31% (CI, 17%-51%;
igure 1B).
The EFS distributions differed signiﬁcantly de-
Figure 1. A, Event-free and overall survival after BMT fending on the remission status at BMT (P  .0007; F
2igure 2). The EFS appeared greater in patients who
nderwent transplantation in ﬁrst remission, com-
ared with patients who underwent transplantation
fter relapse. The few patients with primary induction
ailure (3 of whom received autografts and 4 of whom
eceived allografts) did poorly, although 1 of the
eaths was not cancer related.
The EFS distributions for autologous and alloge-
eic BMT are shown in Figure 3A, and the actuarial
elapse rates are shown in Figure 3B. Autologous
MT thus far has conferred a statistically signiﬁcant
dvantage in EFS (P  .005), with an estimated me-
ian of 43 months, versus only 5.5 months for alloge-
eic BMT. Not unexpectedly, the early failure rate
as higher in the allogeneic subgroup. However,
iven that the allogeneic group contained a higher
roportion of patients who underwent transplantation
or disease relapse, we also compared survival out-
omes in patients who underwent transplantation in
rst partial or complete remission. It is interesting to
ote that for BMT in ﬁrst remission, there was only 1
elapse in the allogeneic subgroup, versus 5 relapses in
he autologous subgroup (ﬁgure not shown), but the
igniﬁcance of this is unclear given the relatively small
tle cell lymphoma. B, Actuarial relapse rate after BMT.igure 2. Event-free survival according to remission status at BMT.
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Bample size. Notably, the EFS distributions were not
tatistically different for autologous versus allogeneic
MT performed in ﬁrst remission (Figure 3C), with
rossing of the survival curves and a projected 3-year
FS of approximately 70% with either approach.
igure 3. A, Event-free survival according to type of BMT. B, Act
utologous versus allogeneic BMT performed in ﬁrst remission.
able 3. Univariate Predictors of Survival after BMT
Variable
Event-Free Sur
HR 95% CI
ge >50 y 1.82 0.62-5.33
plenomegaly 1.50 0.68-3.29
tage III or IV 1.47 0.44-4.93
R-1* 2.08 0.55-7.88
MT after >1 relapse† 2.63 1.09-6.37
rimary induction failure‡ 5.91 2.11-16.5
ositive marrow at BMT§ 1.15 0.32-4.08
u/Cy conditioning 0.62 0.25-1.51
llogeneic BMT 2.86 1.32-6.19
VHD 3.45 1.43-8.35
R indicates hazard ratio; CI, conﬁdence interval; Bu, busulfan; C
host disease.
Compared with BMT in ﬁrst complete remission.
Compared with BMT in ﬁrst remission, excluding primary induct
Compared with BMT in ﬁrst remission.
Morphologic and/or ﬂow cytometric involvement.
Compared with cyclophosphamide/total body irradiation.
B&MTrognostic Factors
The univariate analyses for EFS and relapse risk
re reported in Table 3. Allogeneic BMT and BMT
erformed after relapse were associated with a signif-
elapse rate according to type of BMT. C, Event-free survival after
Relapse
P Value HR 95% CI P Value
.27 1.80 0.39-8.27 .45
.31 1.35 0.42-4.27 .62
.53 1.10 0.24-5.04 .91
.28 3.74 0.43-32.2 .23
.03 1.58 0.39-6.32 .52
.001 6.90 1.60-29.8 .01
.83 4.48 1.21-16.7 .03
.29 2.42 0.69-8.53 .17
.008 1.59 0.48-5.33 .45
.006 2.11 0.46-9.82 .34
phosphamide; PR-1, ﬁrst partial remission; GVHD, graft-versus-
lure.uarial rvival
y, cyclo
ion fai43
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4cantly inferior EFS (P  .008 and P  .03, respec-
ively). Although the HRs for relapse exceeded 1,
hese variables were not statistically signiﬁcant predic-
ors of relapse. Primary induction failure also pre-
icted a poor outcome, with a 6-fold higher risk of
aving an event (P  .001) and a 7-fold higher risk of
elapse (P  .01). GVHD was associated with a sig-
iﬁcantly poorer EFS (likely because of its association
ith allogeneic BMT) but was not an independent
redictor. BMT in ﬁrst partial versus ﬁrst complete
emission and age 50 years were also associated with
n inferior outcome, but the effects were not statisti-
ally signiﬁcant (Table 3).
Residual morphologic and/or ﬂow cytometric
one marrow involvement before high-dose ther-
py, although not a signiﬁcant predictor of EFS,
as associated with a 4-fold increased risk of re-
apse (P  .03). When separately assessed, residual
one marrow involvement by morphologic criteria
redicted a signiﬁcantly heightened relapse risk,
ith a trend toward higher relapse with residual
ow cytometric abnormalities (data not shown). No
tatistically signiﬁcant effect on EFS or relapse risk
as seen with stage III or IV disease, “B” symptoms,
plenomegaly, gastrointestinal involvement, lym-
hocytosis, or year of BMT as a continuous variable
data not shown).
On multiple regression analysis (Table 4), alloge-
eic BMT and BMT performed in the relapsed setting
redicted a 3-fold higher risk of an inferior EFS.
hese variables were not statistically signiﬁcant pre-
ictors of relapse, but they were explored because of
he strength of their association with EFS. Similar to
he univariate model, primary induction failure
merged as an independent predictor of inferior out-
ome, conferring a 5-fold greater risk of having an
vent (P  .002) or of relapsing (P  .03). Residual
one marrow involvement by lymphoma at the time of
MT also was an independent, signiﬁcant predictor of
elapse. Year of BMT was not found to be an inde-
endent predictor of EFS.
An earlier multiple regression model for EFS (be-
ore the ﬁnal step-down procedure) additionally re-
able 4. Multiple Regression Models for BMT Outcomes
Variable
Event-Free
HR 95% CI
MT after >1 relapse* 2.98 1.20-7.39
rimary induction failure† 5.39 1.89-15.4
llogeneic BMT 3.03 1.35-6.82
arrow involvement at BMT‡ — —
R indicates hazard ratio; CI, conﬁdence interval.
Compared with BMT in ﬁrst remission, excluding patients with p
Compared with BMT in ﬁrst remission.
Morphologic and/or ﬂow cytometric involvement.ealed a trend toward better outcomes with age 50
4ears (HR, 0.39; P  .10) and the use of Bu/Cy
onditioning (HR, 0.52; P  .17). GVHD was also
ssociated with a lower HR, but this did not reach
tatistical signiﬁcance (HR, 0.47; 95% CI, 0.20-1.34;
 .31). A separate analysis of low-grade versus
igh-grade GVHD was not feasible, but the reversal
f HRs on univariate (HR 3.45) and multiple regres-
ion analyses is interesting.
ISCUSSION
High-dose systemic therapy with BMT has the
otential to prolong the survival of patients with man-
le cell lymphoma. Our outcomes for autologous and
llogeneic BMT compare favorably to those previ-
usly reported [20-22]. We had a fair number of older
atients in this study, with a median age at BMT of 55
ears. Furthermore, we did not exclude patients from
nalysis on the basis of primary induction failure or
esistant relapse.
As with other non-Hodgkin lymphomas, the op-
imal timing of treatment intensiﬁcation in mantle cell
ymphoma is a matter of debate. Some have not found
signiﬁcant difference in outcome according to the
iming of transplantation for this disease [5]. Our data
uggest that timing is an important consideration.
ost patients in this series underwent transplantation
n ﬁrst remission, and this was associated with a supe-
ior EFS on multiple regression analysis. Others have
ikewise found that the beneﬁt of BMT is most pro-
ounced either in ﬁrst remission or before multiple
elapses [20,23,24]. In one of the largest series, it was
ound that patients who underwent transplantation in
rst complete remission had a signiﬁcantly longer
rogression-free survival and OS than the rest of the
ohort [21]. We did not ﬁnd a statistically signiﬁcant
dvantage to performing transplantation in ﬁrst com-
lete versus ﬁrst partial remission, although there was
suggestion to that effect. However, this question is
est addressed prospectively, given the potential vari-
bility in the number of debulking cycles given before
MT and in the type of ﬁrst-line chemotherapy.
l Relapse
P Value HR 95% CI P Value
.02 1.49 0.35-6.47 .59
.002 5.26 1.17-23.7 .03
.007 2.05 0.55-7.60 .29
— 4.40 1.15-16.8 .03
induction failure.Surviva
rimaryWe had only a few patients with primary induc-
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Bion failure, but their outcomes were poor. In the
reviously described series [21], the 11 patients with
efractory disease did not do worse, but others have
lso described poor outcomes in patients with resistant
isease. In a series of allogeneic BMT for mantle cell
ymphoma, for instance, patients with chemosensitive
isease had an OS of 90%, compared with 44% for
efractory disease [9].
There are thus far limited published data on my-
loablative allogeneic BMT for mantle cell lym-
homa. Two larger series have found a 2-year relapse-
ree survival of at least 50% [9,10], although an earlier
tudy of allogeneic BMT (mainly or exclusively in the
elapsed setting) found a 3-year EFS of 12% [25]. Not
nexpectedly, allogeneic BMT was associated with a
igher procedure-related mortality than autologous
MT in our analysis. However, an allogeneic ap-
roach may ultimately confer an advantage in longer-
erm relapse-free survival. Evidence of a graft-versus-
ymphoma effect has been demonstrated in other
ymphoid and myeloid malignancies, with lower re-
apse rates after allogeneic compared with autologous
ransplantation [26-28] and remissions achieved after
onor lymphocyte infusion. A graft-versus-lymphoma
ffect in mantle cell lymphoma has been suggested by
he association between remission status and develop-
ent of GVHD and the conversion from molecularly
etectable disease after BMT to undetectable disease
ver time [9]. Also of interest are the recent data on
educed-intensity approaches. Although results from
n earlier report were disappointing [11], more recent
ata in poor-risk, heavily pretreated patients with
antle cell lymphoma seem promising [12].
Our data with up-front transplantation seem
articularly promising, with estimated 3-year EFS
ates for either autologous or allogeneic transplan-
ation approaching 70%. Favorable results have
imilarly been reported for up-front autologous
MT in patients who respond to ﬁrst-line chemo-
herapy, with an estimated 3-year EFS of 83% in
ne series [29]. Although up-front mortality is
learly higher with allogeneic transplantation, the
tatistical disadvantage to allogeneic transplantation
ay partly reﬂect a poorer-risk group of patients, as
as been seen in other studies [28].
The curative potential of BMT remains to be
eﬁned for mantle cell lymphoma, as do the optimal
iming and type of treatment intensiﬁcation. The dis-
inct natural history of this disease compared with that
f low-grade lymphomas warrants dedicated study in
rospective clinical trials, with clear deﬁnitions of his-
opathologic inclusion criteria. Our analysis, as well as
ome others, suggests that high-dose therapy per-
ormed early in the course of the disease may improve
rognosis. If there is a beneﬁt to treatment intensiﬁ-
ation, it is most evident early in the disease course. It
emains to be seen whether such observations reﬂect
B&MTatient selection or a true advantage to treatment
ntensiﬁcation [6]. Longer-term follow-up and more
atients are needed to determine the comparative ef-
cacy of autologous and allogeneic BMT for this dis-
ase. There are potentially fewer transplant-related
omplications in patients who are less heavily pre-
reated [8], such that offering BMT earlier in the
reatment course may confer an advantage.
More prospective data on high-dose therapy in the
etting of clinical trials are needed for mantle cell
ymphoma. Comparison with historical outcomes
rom conventional chemotherapy is potentially hin-
ered by selection bias, variability in the efﬁcacy of
onventional chemotherapeutic regimens, and vari-
bility in histopathologic inclusion criteria. The cur-
tive potential of BMT for mantle cell lymphoma has
ppropriately been disputed [5]. Longer follow-up is
equired to determine whether the survival curve
eaches a plateau, which has generally not been ap-
reciated with trials of autologous BMT to date. Late
elapses have been noted after autologous BMT for
antle cell lymphoma [29,30], and we noted a late
elapse after allogeneic BMT. Given the potential for
graft-versus-lymphoma effect, fully ablative or re-
uced-intensity allogeneic BMT is of particular inter-
st in this disease, alone or in combination with bio-
ogic or immunomodulatory therapies.
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